menu
    • menu

    Company profile for Neuraptive Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The Company’s franchise therapeutics product is designed for administration during surgery to improve outcomes for patients impacted by acute nerve injury repairs and reconstructive surgical procedures involving p...
    Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The Company’s franchise therapeutics product is designed for administration during surgery to improve outcomes for patients impacted by acute nerve injury repairs and reconstructive surgical procedures involving peripheral nerves. Also, the Company is developing a suite of advanced microsurgical instruments for use in peripheral nerve surgery.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Neuraptive TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Logan Square Suite 1930 Philadelphia, PA 19103
    Telephone
    Telephone
    +1.617.794.6442
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://neuraptive.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neuraptive Enrolls First Patient in Ph 3 NTX-001 Nerve Trial
    Neuraptive Enrolls First Patient in Ph 3 NTX-001 Nerve Trial

    02 Oct 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-10-02/neuraptive-therapeutics-inc-announces-first-patient-enrolled-in-phase-3-clinical-trial-evaluating

    PHARMAWEB
    02 Oct 2025
    Share Share
    Neuraptive Therapeutics Announces Phase 2 Interim Results
    Neuraptive Therapeutics Announces Phase 2 Interim Results

    19 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240919597699/en

    BUSINESSWIRE
    19 Sep 2024
    Share Share
    Neuraptive Announces Positive 24-Week Data for NTX-001 in the Phase 2 Study
    Neuraptive Announces Positive 24-Week Data for NTX-001 in the Phase 2 Study

    22 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240222942067/en

    BUSINESSWIRE
    22 Feb 2024
    Share Share
    Neuraptive Receives Orphan Drug Designation for its Lead Development Asset
    Neuraptive Receives Orphan Drug Designation for its Lead Development Asset

    15 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240115132196/en

    BUSINESSWIRE
    15 Jan 2024
    Share Share
    Neuraptive Announces Achievement of Proof of Concept in The Study of NTX-001
    Neuraptive Announces Achievement of Proof of Concept in The Study of NTX-001

    08 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240108340125/en

    BUSINESSWIRE
    08 Jan 2024
    Share Share
    Neuraptive Strengthens its Board of Directors With Appointment of Cary Sucoff
    Neuraptive Strengthens its Board of Directors With Appointment of Cary Sucoff

    27 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230227005033/en

    BUSINESSWIRE
    27 Feb 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search